Stay informed on developments in cancer and oncology diagnosis, prevention and treatment through these curated webinars. As the race toward a cure for cancer continues, advances in cancer research are constantly revealed as innovation in the field of oncology progresses.
The majority of disease-associated genetic variants are thought to have regulatory effects, including disruption of transcription factor (TF) binding and alteration of downstream gene expres...
One of the central tenets of biology is that our genetics—our genotype—influences the physical characteristics we manifest—our phenotype. But with more than 25,000 human ge...
In real-world evidence (RWE), temporal shifts in clinical knowledge and practice need to be adjusted for treatment effect assessment. We use electronic health records (EHR) data to 1) assess...
Immuno-oncology (IO) is a type of cancer treatment that uses the body's immune system to fight cancer. It works by stimulating the immune system to recognize and attack cancer cells, while le...
The 21st Century Cures Act, along with the FDA's Real-World Evidence (RWE) framework, has established a foundation for incorporating real-world data (RWD) into regulatory decision-making...
COSMIC is the world’s largest and most comprehensive somatic mutations resource. COSMIC’s contents are manually curated by PhD-level experts from high-quality scientific literatu...
There are known health outcome disparities among those with pancreatic neuroendocrine tumors (pNET) of minority race and those living with adverse social determinants of health (SDOH) (rural...
Antibody-based cancer therapies have clear advantages over chemotherapeutic drugs thanks to their high specificity and low risk of side effects. However, it can be difficult to identify targ...
The increasing quantity and quality of spatially resolved omics data provide a unique opportunity to explore the complex molecular mechanisms that take place in biological systems. However,...
The tumor-associated microbiota is an inherent component of the tumor microenvironment across various human cancer types1. Although members of tumor-associated microbiomes can be identified...
Genomic research has long been skewed toward European populations, leading to significant underrepresentation of Non-European groups in both research studies and genomic databases. This bias...
In the ever-evolving landscape of cancer therapy, immune checkpoint inhibitors have emerged as promising avenues for therapeutic antibody development. Our presentation will share GenScript&#...
The elegant and well-orchestrated molecular players responsible for normal neurodevelopment harbor the capacity for detrimental repercussions if mis-expressed at the wrong time, or in the wr...
Successful cancer patient advocacy has many components. Patients and survivors are in the best position to tell their stories and advocate for better care and treatment. However, with few su...
Competing to offer a comprehensive genomic profiling service for solid or hematology oncology tumor samples is challenging, especially as panels increase in size and complexity. QIAGEN Clini...
Cancer is the #1 cause of death by disease in children. Over the last few decades, the survival rates for children with cancer have improved. These gains have been made by brilliant dedicate...
Reliable expression of recombinant proteins in human, CHO, or insect cells is essential for many aspects of biomedical research and drug development, but is often hampered by low expression...
Conventional imaging studies such as ultrasound, computed tomography, and magnetic resonance imaging are increasingly detecting small renal masses, which are interpreted by radiologists as h...
In the world of advanced medical research, the convergence of synthetic biology and cellular immunotherapy has inaugurated a new era in field of cancer treatment. Simultaneously, life scienc...
To determine efficacy of specific complementary therapies to advance evidence-based, integrative healthcare, the complementary modality should first be introduced to stakeholders to determin...
Cancer neoantigens arise from protein-altering somatic mutations in tumor and rank among the most promising next-generation immuno-oncology agents when used in combination with immune checkp...
Immunotherapy has changed the landscape of oncology, improving survival rates for many patients across a variety of malignancies. Two antibody-based immunotherapies, immune checkpoint inhibi...
Rapid screening and speed of scale-up in protein therapeutics are critical factors in today’s immuno-oncology workflow. The ability to swiftly develop novel therapies often depends on...
Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that i...
Hematuria (blood in urine) may occur in up to 10% of the general population and results in costly evaluation to ensure it is of no consequence, i.e., no bladder cancer (BCa) is present since...
Genomic analysis of cancer cells revealed comprehensive mechanism of tumorigenesis in human patients. Among the abnormalities discovered so far, CNVs accounted for a great portion of all the...
Neoantigen vaccines are a type of personalized cancer vaccine. While clinical trials have shown promising results, it is important to note that neoantigen vaccines are still in the early sta...
The majority of disease-associated genetic variants are thought to have regulatory effects, including disruption of transcription factor (TF) binding and alteration of downstream gene expres...
